NCT06869187 - Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 28, 2025

Primary Completion Date

February 27, 2026

Study Completion Date

March 13, 2026

Conditions

Bipolar Disorder Depression

Interventions

DRUG

ABX-002

ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.

Trial Locations (11)

10019

NOT_YET_RECRUITING

Autobahn Site #211, New York

10022

WITHDRAWN

Autobahn Site #202, New York

10314

RECRUITING

Autobahn Site #204, Staten Island

11235

RECRUITING

Autobahn Site #203, Brooklyn

33014

RECRUITING

Autobahn Site #212, Miami

94596

NOT_YET_RECRUITING

Autobahn Site #213, Walnut Creek

06416

RECRUITING

Autobahn Site #201, Cromwell

06106

NOT_YET_RECRUITING

Autobahn Site #210, Hartford

08002

RECRUITING

Autobahn Site #208, Cherry Hill

08690

RECRUITING

Autobahn Site #209, Hamilton

08053

RECRUITING

Autobahn Site #205, Marlton